Key result
IGF-I inhibited GH promoter activity by more than 50% in a time- and dose-related manner, an effect completely eliminated by the PI3 kinase inhibitor wortmannin.
IGF-I suppresses growth hormone gene expression at the transcriptional level primarily through the PI3 kinase-mediated signaling pathway in a rat somatotroph cell model.
Preclinical rat somatotroph data; extends IGF-I negative feedback mechanism via PI3K but leaves open in vivo and clinical relevance.
Although insulin-like growth factor-I (IGF-I) is shown to have a suppressive effect on GH gene expression at the pituitary level, its molecular mechanism has not yet been clarified. To study the issue, we established a new in vitro system using MtT/S, a recently established rat somatotroph tumor cell line that retains the basic characteristics of somatotroph function. Plasmids containing the GH 5' promoter (approximately 1.75 kb or shorter)-luciferase fusion gene were transfected stably or transiently into the cells, and the effect of IGF-I on the GH promoter activity was estimated by a luciferase assay. The results showed that IGF-I inhibited GH promotor activity (more than 50% suppression) in a time- and dose-related manner. IGF-I also inhibited GH secretion. A study using deletion mutants of the GH promoter revealed that the negative effect was maintained in the shortest construct (-80 to +6), suggesting that IGF-I-related factor is acting at the region very close to the minimal promoter. Interestingly, the negative effect was completely eliminated by a PI3 kinase inhibitor wortmannin (1 microM), whereas a MAP kinase inhibitor PD98059 (20 microM) or S6 kinase inhibitor rapamycin (10 nM) did not influence the effect. Our results suggest that IGF-I suppresses GH gene expression at the transcriptional level and that the PI3 kinase-mediated signaling pathway plays a major role in the negative effect of IGF-I. We believe that our system using MtT/S cells is an excellent experimental model system for studying the cellular and molecular mechanisms of the transcriptional regulation of GH in vitro.
No takes yet. Share an insight, caveat, or question.
Niiori-Onishi et al. (1999) studied GH gene expression in somatotroph cells. Insulin-like growth factor-I (IGF-I) was evaluated on GH promoter activity. IGF-I inhibited GH promoter activity by more than 50% in a time- and dose-related manner, an effect completely eliminated by the PI3 kinase inhibitor wortmannin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: